Kenyan Manufacturer Licensed to Prepare for Possible Alimatravir Production
By Daily Report KE | Updated October 9, 2026
Kenya’s Universal Corporation Limited (UCL) is among generic manufacturers named in Merck’s voluntary licensing plan to prepare for possible production of alimatravir (MK-8527), an investigational once-monthly oral medicine being studied for HIV prevention.
Alimatravir is not an approved HIV-prevention medicine and is not available for routine use. It remains in Phase 3 clinical trials. Production and supply for patients would depend on trial results, regulatory review and approval.
What the licensing plan means
UNAIDS said in August 2026 that Merck had announced voluntary licensing agreements with generic manufacturers, including UCL in Kenya, to prepare for possible production if trials succeed. A licence permits preparation under the agreement; it does not mean that a medicine has passed trials, received approval, or will necessarily reach the market.
What is alimatravir?
Alimatravir, also known as MK-8527, is being studied as a monthly oral option for pre-exposure prophylaxis (PrEP). PrEP is medicine used by HIV-negative people to reduce the risk of acquiring HIV. The investigational status of alimatravir means that readers should continue to rely on approved prevention options and speak with a qualified health provider about their circumstances.
What happens next
Merck said its Phase 3 studies were expected to report in 2027. Researchers and regulators must assess the evidence before any decision on approval. Until then, claims about the pill’s effectiveness, safety in routine use, price or availability should be treated as unconfirmed.
